Analysis Projects Oral Semaglutide Could Prevent Over 118,000 US Cardiovascular Events

A new mathematical framework projects oral semaglutide could prevent over 118,000 major cardiovascular events in the US. This analysis, based on the SOUL trial, indicates the medication significantly reduced adverse cardiovascular events in type 2 diabetes patients with established cardiovascular or chronic kidney disease. This suggests a substantial potential public health benefit in managing high-risk individuals.